Skip to main content
PMC home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1971 Dec;9(6):713–719.

Delayed cutaneous sensitivity reactions to autologous Burkitt lymphoma protein extracts. Results of a prospective two and a half year study

A Z Bluming, J L Ziegler, L Fass, R B Herberman
PMCID: PMC1713125  PMID: 5158270

Abstract

Positive delayed cutaneous sensitivity reactions to protein extracts of autologous Burkitt lymphoma cells were observed in fifteen of thirty patients tested in clinical systemic remission and in only one of sixteen patients tested with active extradural disease. Positive responding patients who eventually relapsed had significantly longer remission durations than did their negative responding counterparts. Seven patients with positive reactions were negative when retested in relapse. Positive reactions were not observed at extract protein concentrations of 0·1 mg/ml and were maximally evident at 1 mg/ml. Negative skin tests could not be attributed to generalized anergy because of the simultaneous observation of positive reactions to common antigens in over half the negative responders. Cutaneous reactivity to autologous tumour extract may serve as a sensitive test for extradural disease activity, and, because of its association with remission duration, suggests a role for the specifically sensitized lymphocyte in tumour regression and prognosis.

Full text

PDF
713

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alexander P., Bensted J., Delorme E. J., Hall J. G., Hodgett J. The cellular immune response to primary sarcomata in rats. II. Abnormal responses of nodes draining the tumour. Proc R Soc Lond B Biol Sci. 1969 Nov 18;174(1035):237–251. doi: 10.1098/rspb.1969.0090. [DOI] [PubMed] [Google Scholar]
  2. Fass L., Herberman R. B., Ziegler J. Delayed cutaneous hypersensitivity reactions to autologous extracts of Burkitt-lymphoma cells. N Engl J Med. 1970 Apr 2;282(14):776–780. doi: 10.1056/NEJM197004022821404. [DOI] [PubMed] [Google Scholar]
  3. Fass L., Herberman R. B., Ziegler J., Morrow R. H., Jr Evaluation of the effect of remission plasma on untreated patients with Burkitt's lymphoma. J Natl Cancer Inst. 1970 Jan;44(1):145–149. [PubMed] [Google Scholar]
  4. Hellström I., Evans C. A., Hellström K. E. Cellular immunity and its serum-mediated inhibition in Shope-virus-induced rabbit papillomas. Int J Cancer. 1969 Sep 15;4(5):601–607. doi: 10.1002/ijc.2910040504. [DOI] [PubMed] [Google Scholar]
  5. Hellström I., Hellström K. E. Studies on cellular immunity and its serum mediated inhibition in Moloney-virus-induced mouse sarcomas. Int J Cancer. 1969 Sep 15;4(5):587–600. doi: 10.1002/ijc.2910040503. [DOI] [PubMed] [Google Scholar]
  6. Henle G., Henle W., Clifford P., Diehl V., Kafuko G. W., Kirya B. G., Klein G., Morrow R. H., Munube G. M., Pike P. Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups. J Natl Cancer Inst. 1969 Nov;43(5):1147–1157. [PubMed] [Google Scholar]
  7. Heppner G. H. Studies on serum-mediated inhibition of cellular immunity to spontaneous mouse mammary tumors. Int J Cancer. 1969 Sep 15;4(5):608–615. doi: 10.1002/ijc.2910040505. [DOI] [PubMed] [Google Scholar]
  8. Klein G., Clifford P., Henle G., Henle W., Geering G., Old L. J. EBV-associated serological patterns in a Burkitt lymphoma patient during regression and recurrence. Int J Cancer. 1969 Jul 15;4(4):416–421. doi: 10.1002/ijc.2910040406. [DOI] [PubMed] [Google Scholar]
  9. Klein G., Clifford P., Klein E., Stjernswärd J. Search for tumor-specific immune reactions in Burkitt lymphoma patients by the membrane immunofluorescence reaction. Proc Natl Acad Sci U S A. 1966 Jun;55(6):1628–1635. doi: 10.1073/pnas.55.6.1628. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  11. Mikulska Z. B., Smith C., Alexander P. Evidence for an immunological reaction of the host directed against its own actively growing primary tumor. J Natl Cancer Inst. 1966 Jan;36(1):29–35. [PubMed] [Google Scholar]
  12. Old L. J., Boyse E. A., Oettgen H. F., Harven E. D., Geering G., Williamson B., Clifford P. Precipitating antibody in human serum to an antigen present in cultured burkitt's lymphoma cells. Proc Natl Acad Sci U S A. 1966 Dec;56(6):1699–1704. doi: 10.1073/pnas.56.6.1699. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Oren M. E., Herberman R. B. Delayed cutaneous hypersensitivity reactions to membrane extracts of human tumour cells. Clin Exp Immunol. 1971 Jul;9(1):45–56. [PMC free article] [PubMed] [Google Scholar]
  14. Osunkoya B. O. Evidence for anti-Burkitt tumour globulins in Burkitt tumour patients and healthy individuals. Br J Cancer. 1967 Jun;21(2):302–311. doi: 10.1038/bjc.1967.33. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Ziegler J. L., Morrow R. H., Jr, Fass L., Kyalwazi S. K., Carbone P. P. Treatment of Burkitt's tumor with cyclophosphamide. Cancer. 1970 Aug;26(2):474–484. doi: 10.1002/1097-0142(197008)26:2<474::aid-cncr2820260232>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES